+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic M1 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic M1 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Congenital Adrenal Hyperplasia- Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Adrenal Hyperplasia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Propionic Acidemia - Pipeline Insight, 2025 - Product Thumbnail Image

Propionic Acidemia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
GM2 Gangliosidosis - Pipeline Insight, 2025 - Product Thumbnail Image

GM2 Gangliosidosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Macular Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Macular Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Farber's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Farber's Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
GM1 Gangliosidosis - Pipeline Insight, 2025 - Product Thumbnail Image

GM1 Gangliosidosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Acute Gout Flare - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Gout Flare - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
WHIM Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

WHIM Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Maple Syrup Urine Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Maple Syrup Urine Disease- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Morquio Syndrome Mps IV - Pipeline Insight, 2025 - Product Thumbnail Image

Morquio Syndrome Mps IV - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Primordial Dwarfism/ Dwarfism - Pipeline Insight, 2025 - Product Thumbnail Image

Primordial Dwarfism/ Dwarfism - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Protein Degraders - Pipeline Insight, 2025 - Product Thumbnail Image

Protein Degraders - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Adrenal Crisis - Pipeline Insight, 2025 - Product Thumbnail Image

Adrenal Crisis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more